July 13, 2016 – Monona, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that George Hansrote will join the company as Vice President of Project Delivery, to manage the construction of the SHINE radioisotope production facility. The appointment comes as the company prepares to build its facility in Janesville, Wisconsin, after receiving its construction permit from the U.S. Nuclear Regulatory Commission in February. The SHINE facility will produce molybdenum-99 (moly-99) and other medical isotopes.
Mr. Hansrote has over 30 years of experience in project management, having spent the first half of his career working on nuclear power projects, and the second half working on first-of-a-kind nuclear facilities. Immediately prior to joining SHINE, he served as the Executive Director, Nuclear Dismantling & Decommissioning for CB&I, Power Division. Mr. Hansrote has an established track record of successfully managing large-scale projects around the world, including projects at Sellafield in the UK, URENCO’s National Enrichment Facility, Los Alamos National Laboratory, and Hanford, among many others, with responsibility for previous projects ranging from $100 million to $3 billion, with limits of authority as high as $10 million. Mr. Hansrote holds B.S. degrees in both Mechanical Engineering with an Aerospace Option and Biology with a Chemistry Minor, as well as an A.S. in Architecture.
“I’m very excited to have George join the SHINE team as we move into the build phase of our medical isotope plant in Janesville,” said Greg Piefer, CEO of SHINE. “He’s led numerous commercial nuclear and first-of-a-kind nuclear projects to success, and has a strong educational background and commitment to safety. These characteristics make him ideal for managing the construction and operational ramp-up of the SHINE facility.”